Flupenthixol Decanoate in Methamphetamine Smoking - 1

The purpose of this study is to evaluate the safety and efficacy of flupenthixol decanoate for treatment of methamphetamine dependence. Also, study will compare flupenthixol with desipramine in blocking methamphetamine self-administration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Substance-related Disorders Chemically-Induced Disorders Mental Disorders

Age range

22 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Friends Research Institute

Los Angeles, California, 90025, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Please contact site for information.

Treatment and study plan

Flupenthixol

Drug

Primary outcomes

Methamphetamine use

Sponsors and collaborators

Lead sponsor

National Institute on Drug Abuse (NIDA)

Nih

Collaborators

Friends Research Institute, Inc.

Registry information

Official study title

Flupenthixol Decanoate in Methamphetamine Smoking

Important dates

Study start: 1994
Study completion: 1996
First posted: Sep 21, 1999
Registry last updated: Jan 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed